Tax News Update    Email this document    Print this document  

August 11, 2022
2022-1218

Wednesday, August 17 | What does the Inflation Reduction Act mean for life science companies? (12 pm ET)

The Inflation Reduction Act includes significant new policies aimed at reining in consumer drug costs that will affect pharmaceutical companies’ strategic and operational decisions now and in the long term. Connect to this webcast to hear from EY policy, strategy and tax professionals about the legislation and potential market implications.

Learn more about:

  • Key elements of the Inflation Reduction Act directed at pharmaceutical pricing and patient access
  • How Medicare will now be able to negotiate drug prices outside the initial exclusivity period
  • Inflationary rebates and out-of-pocket cost caps
  • How much longer the enhanced Affordable Care Act subsidies will be expanded
  • Effect of the legislation on the commercialization of pharmaceuticals and investments
  • Tax changes affecting pharmaceutical companies

Date: Wednesday, August 17, 2022

Time: 12 pm ET

Registration: View archive here.

Panelists

  • Arda Ural, PhD, EY Americas Industry Markets Leader, Health Sciences & Wellness, Principal, Ernst & Young LLP

  • Muna Tuna, US Market Access, Pricing and Reimbursement Leader, Health Sciences & Wellness, Principal, Ernst & Young LLP

  • Eduardo Schur, EY US Health Sciences & Wellness Commercial Strategy and R&D Lead

  • Heather Meade, Washington Council Ernst & Young, Principal, Ernst & Young LLP

  • Laura Dillon, Washington Council Ernst & Young, Senior Manager, Ernst & Young LLP

  • Jonny Lindroos, International Tax and Transactions Services, Principal, Ernst & Young LLP

  • Joshua Cohen, Senior Advisor, Life Sciences, Ernst & Young LLP

Learn about and register for EY Tax Webcasts

Register for EY’s Tax News Update so you don’t miss any EY Tax Webcasts: taxnews.ey.com/register

 

The information contained herein is general in nature and is not intended, and should not be construed, as legal, accounting or tax advice or opinion provided by Ernst & Young LLP to the reader. The reader also is cautioned that this material may not be applicable to, or suitable for, the reader's specific circumstances or needs, and may require consideration of non-tax and other tax factors if any action is to be contemplated. The reader should contact his or her Ernst & Young LLP or other tax professional prior to taking any action based upon this information. Ernst & Young LLP assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect the information contained herein.

 

Copyright © 1996 – 2024, Ernst & Young LLP

 

All rights reserved. No part of this document may be reproduced, retransmitted or otherwise redistributed in any form or by any means, electronic or mechanical, including by photocopying, facsimile transmission, recording, rekeying, or using any information storage and retrieval system, without written permission from Ernst & Young LLP.

 

EY US Tax News Update Master Agreement | EY Privacy Statement